Abstract: Methods are provided for treating a subject with a therapeutic dose of anti-CD47 agent by administering a primer agent prior to administering a therapeutically effective dose of an anti-CD47 agent to the subject.

Abstract: The disclosure relates to a specifically static mixer for mixing two components, with a housing, in which a mixing element is accommodated, and an input part with a first intake and a diametrically opposite second intake, wherein, within the input part, a first channel is formed between the first intake and the mixing chamber and a second channel is formed between the second intake and the mixing chamber. The first channel extends radially inward from the first intake and opens into a central opening in the cover. The second channel has two partial channels as storage chambers not leading into the mixing chamber, and two intake sections located radially within the storage chambers and leading into the mixing chamber. The intake sections branch off the respective storage chambers, extend inward in the opposite direction to the first channel and open into the central opening in the cover.

Abstract: A mounting device for holding a hollow cylindrical object, particularly a screw cap, in a printing system, comprises a support member, and a mandrel for receiving a hollow cylindrical object arranged at the support member, and a heating device for heating the hollow cylindrical object mounted at the mandrel. A printing system for printing on hollow cylindrical objects, preferably screw caps, comprises at least one mounting device, and at least one printhead configured to print on surfaces of cylindrical objects, preferably screw caps.

Abstract: Described is a combination therapy of (i) a multifunctional antibody having specificity for CD30 and CD16A and (ii) an anti-PD-1 antibody for the treatment of a tumor, in particular Hodgkin lymphoma.

Abstract: A semiconductor device includes a semiconductor body comprising a first surface and an edge surface, a contact electrode formed on the first surface and comprising an outer edge side, and a passivation layer section conformally covering the outer edge side of the contact electrode. The passivation layer section is a multi-layer stack comprising a first layer, a second layer, and a third layer. Each of the first, second and third layers comprise outer edge sides facing the edge surface and opposite facing inner edge sides. The outer edge side of the contact electrode is disposed laterally between the inner edge sides and the outer edge sides of each layer. The inner and outer edge sides of the third layer are closer to the outer edge side of the electrode than the respective inner and outer edge sides of the first and second layer.

Abstract: Methods are provided for enhancing immunization strategies by manipulation, e.g. in vitro manipulation, of phagocytic antigen presenting cells. In the methods of the invention, phagocytic antigen presenting cells (phAPC) are incubated with a particulate antigen in the presence of an anti-CD47 agent in a dose and for a period of time sufficient to allow the phAPC to phagocytose the particulate antigen, which process generates a “loaded” phAPC. The loaded phAPC is contacted with a population of T cells matched for at least one major histocompatibility locus with the phAPC, where the T cells are stimulated after contacting to generate an effector response against an epitope or epitopes present on the particulate antigen.

Abstract: Methods are provided herein for determining and administering optimized dosing of therapeutic anti-CD47 agents, in a schedule that provides safe escalation of dose while achieving a therapeutic level in a clinically effective period of time. The methods can comprise the steps of clearance, escalation, and maintenance. In one embodiment the dosing regimen administers an initial (i) sub-therapeutic dose of an anti-CD47 agent or (ii) a cytoreductive therapy to achieve a safe level of circulating tumor cells for subsequent treatment (clearance); escalating the dose of an anti-CD47 agent until a therapeutic dose is reached (escalation); and maintaining the therapeutic dose for a period of time sufficient to reduce tumor cells in the bone marrow of the patient (maintenance). In an alternative dosing regimen, a patient determined to have a safe level of circulating tumor cells at presentation is treated by the steps of escalation and maintenance without initial clearance.

Abstract: Methods are provided for treating a subject with a therapeutic dose of anti-CD47 agent by administering a primer agent prior to administering a therapeutically effective dose of an anti-CD47 agent to the subject.

Abstract: Methods are provided for targeting cells for depletion, including without limitation cancer cells, in a regimen comprising contacting the targeted cells with a combination of agents, including (i) an agent that blockades CD47 activity; and (ii) an antibody that specifically binds to EGFR. In some embodiments the cancer cells have a mutated form of one or more of KRAS, NRAS or BRAF. The level of depletion of the targeted cell is enhanced relative to a regimen in which a single agent is used; and the effect may be synergistic relative to a regimen in which a single agent is used.

Abstract: Methods are provided for treating a subject with a therapeutic dose of anti-CD47 agent by administering a primer agent prior to administering a therapeutically effective dose of an anti-CD47 agent to the subject.

Abstract: The invention relates to a method for automatically and dynamically assigning the responsibility for tasks to the available computing components in a highly distributed data-processing system. The invention relates to a method by means of which the assignment of the responsibility for certain tasks (partitions) is adapted in a highly distributed data-processing system.

Abstract: Methods are provided for targeting cells for depletion, including without limitation cancer cells, in a regimen comprising contacting the targeted cells with a combination of immunoregulatory agents. The level of depletion of the targeted cell is enhanced relative to a regimen in which a single agent is used; and the effect may be synergistic relative to a regimen in which a single agent is used.

Abstract: An application system is presented having a cartridge, at least one first accessory part, for example a stopper, and at least one second accessory part, for example a static or dynamic mixer. The cartridge has at least one container with an outlet opening and at least one outlet connected to the container via the outlet opening on the end face of the cartridge, wherein the at least one outlet can be connected to the at least one first accessory part and the at least one second accessory part such that a seal is produced between the outlet and the respective accessory part. At least one separate seal plane is provided for each accessory part.

Abstract: A semiconductor device includes a silicon carbide body that includes a first section and a second section. The first section is adjacent to the second section. A drift region is formed in the first section and the second section. A lattice defect region is in a portion of the drift region in the second section. A first density of lattice defects, which include interstitials and vacancies in the lattice defect region, is at least double a second density of lattice defects, which include interstitials and vacancies in a portion of the drift region outside the lattice defect region.

Abstract: The invention relates to a method for operating a temperature control device (116) for the thermal conditioning of preforms (14) made of a thermoplastic material in the temperature control device (116), wherein the respective preform (14) is prepared by the thermal conditioning in the temperature control device (116) for a subsequent forming procedure, in which the preform (14) is formed into a container (12) using a forming fluid supplied under a pressure into the preform (14) and in which the preform (14) is stretched in its axial direction by a stretching unit (11), wherein the temperature control device (116) is regulated in its heating power by a heating regulator (400, B) on the basis of a metrologically determined guide value, and is characterized in that a guide value is metrologically detected, from which the stretching force exerted on the preform (14) is derivable.

Abstract: Anti-SIRP? antibodies, including multi-specific anti-SIRP? antibodies, are provided, as are related compositions and methods. The antibodies of the disclosure bind to SIRP? and can block the interaction of CD47 on one cell with SIRP? on a phagocytic cell.

Abstract: A method is for treatment of a disease associated with genotoxic stress-induced inhibitor of nuclear factor-?B kinase/nuclear factor kappa-light chain enhancer of activated B cells (IKK/NF-?B) signaling. The method can include administering a compound to a subject having a cancer exhibiting genotoxic stress induced IKK/NF-?B activation.

Abstract: A method for forming a semiconductor device includes forming a mask layer with a first implantation window on a semiconductor substrate and implanting dopants with a first implantation energy into the semiconductor substrate through the first implantation window to form a first portion of a doping region of the semiconductor device. The mask layer is adapted to form a second implantation window of the mask layer. Further, dopants are implanted with a second implantation energy into the semiconductor substrate through the second implantation window. The second implantation energy differs from the first implantation energy and a lateral dimension of the first implantation window differs from a lateral dimension of the second implantation window.

Abstract: The present disclosure is directed to reducing nocturnal voids by administering a dose of desmopressin over a minimum treatment period compared to before administration, and maintaining or improving the reduction of nocturnal voids over the minimum treatment period.